GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instadose Pharma Corp (OTCPK:INSD) » Definitions » Owner Earnings per Share (TTM)

Instadose Pharma (Instadose Pharma) Owner Earnings per Share (TTM) : 0.00 (As of Nov. 2021)


View and export this data going back to 2019. Start your Free Trial

What is Instadose Pharma Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Instadose Pharma does not have enough data to calculate Owner Earnings per Share (TTM), so as Price-to-Owner-Earnings ratio.


The historical rank and industry rank for Instadose Pharma's Owner Earnings per Share (TTM) or its related term are showing as below:



INSD's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 25.415
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

Instadose Pharma's Earnings per Share (Diluted) for the three months ended in Feb. 2022 was $-0.00. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2022 was $-0.01. It's PE Ratio ratio for today is At Loss.

Instadose Pharma's EPS without NRI for the three months ended in Feb. 2022 was $-0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2022 was $-0.01. It's PE Ratio without NRI ratio for today is At Loss.


Instadose Pharma Owner Earnings per Share (TTM) Historical Data

The historical data trend for Instadose Pharma's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instadose Pharma Owner Earnings per Share (TTM) Chart

Instadose Pharma Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial - - - - -

Instadose Pharma Quarterly Data
May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Instadose Pharma's Owner Earnings per Share (TTM)

For the Drug Manufacturers - Specialty & Generic subindustry, Instadose Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Instadose Pharma's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Instadose Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Instadose Pharma's Price-to-Owner-Earnings falls into.



Instadose Pharma Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Instadose Pharma does not have enough data to calculate Owner Earnings per Share (TTM). Please check Wal-Mart Stores Inc, as your reference.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Instadose Pharma Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Instadose Pharma's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Instadose Pharma (Instadose Pharma) Business Description

Traded in Other Exchanges
N/A
Address
5500 North Service Road, Suite 301, Burlington, ON, CAN, L7L 6W6
Instadose Pharma Corp, formerly Mikrocoze Inc is seeking to create a global distribution platform for medicinal cannabis and cannabinoid oil. The company endeavors to utilize the Global Distribution Platform to open the commercial gateway to a new wholesale marketplace along with providing pharmaceutical industry companies with large, sustainable, consistent, diverse, and low?cost supplies of high?quality medicinal cannabis and cannabinoid oil for use in bulk as an active pharmaceutical ingredient.

Instadose Pharma (Instadose Pharma) Headlines

From GuruFocus